The table below shows Avidity Biosciences, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$650.44M
-$300.87M
-$119.06M
-$136.27M
-$94.81M
-$37.12M
Capital expenditure
$13.32M
$7.07M
$4.23M
$2.82M
$3.74M
$1.09M
Investing cash flow
-$38.03M
-$854.20M
-$130.07M
-$189.96M
-$82.52M
-$7.79M
Dividends paid
-
-
-
-
RNA operating cash flow (10-K history)
Avidity Biosciences, Inc. reported operating cash flow of -$650.44M for fiscal year 2025. That is down 116.2% from -$300.87M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$9.65M (FY 2018) to -$650.44M. Figures come from the company's audited annual reports as filed with the SEC.
